Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc shares valued at $2,085 were purchased by Eisele Jeffrey on Dec 23 ’24. At $33.09 per share, Eisele Jeffrey acquired 63 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Watson David O. sold 5,000 shares, netting a total of over 171,175 in proceeds. Following the sale of shares at $34.23 each, the insider now holds 112,721 shares.
Before that, DAVID OSBORNE WATSON had added 5,000 shares to its account. In a trade valued at $171,175, the Officer bought Apellis Pharmaceuticals Inc shares for $34.23 each.
As published in a research note from Goldman on December 17, 2024, Apellis Pharmaceuticals Inc [APLS] has been rated down from a Buy to a Neutral and the price target has been revised to $36. Analysts at Morgan Stanley started covering the stock with ‘”an Equal-weight”‘ outlook in a report released in late November. As of October 25, 2024, RBC Capital Mkts has initiated its “Sector perform” rating for APLS. Earlier on October 16, 2024, William Blair initiated its rating. Their recommendation was “an Outperform” for APLS stock.
Analyzing APLS Stock Performance
During the last five days, there has been a drop of approximately -3.13%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -44.95%. Shares of the company reached a 52-week high of $73.80 on 01/09/24 and a 52-week low of $24.34 on 11/05/24. A 50-day SMA is recorded $30.51, while a 200-day SMA reached $38.67. Nevertheless, trading volume fell to 1.04 million shares from 1.18 million shares the previous day.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 32.45, which, if violated, would cause prices to drop to 31.94. In the upper region, resistance lies at 33.34. The next price resistance is at 33.73. RSI (Relative Strength Index) is 52.07 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.49, which suggests the price will decrease in the coming days. Percent R is at 69.82%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
